Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Program
-
Field
- Biology
- Medical Sciences
- Economics
- Computer Science
- Engineering
- Science
- Business
- Mathematics
- Social Sciences
- Electrical Engineering
- Law
- Chemistry
- Education
- Environment
- Arts and Literature
- Humanities
- Materials Science
- Philosophy
- Earth Sciences
- Linguistics
- Psychology
- Sports and Recreation
- 12 more »
- « less
-
other immunoassays, RNA interference (siRNA/shRNA knockdown), Colony formation assays, Reporter gene assays (luciferase, GFP-based assays), Basic biochemistry techniques (protein extraction, purification
-
Science fellowship, based in Cambridge, MA. About Alnylam Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with
-
. no País (https://www.fct.pt/wp-content/uploads/2025/02/Tabela_valores_SMM_2025.pdf ). Outros Benefícios: Reembolso do Seguro Social Voluntário (SSV), correspondente ao 1º Escalão da base de incidência
-
constraints such as electromagnetic interference (EMI), thermal stability, and mechanical durability. In parallel, the project will refine and optimize existing machine learning models for fault detection and
-
a two-year Global Patient Safety and Risk Management fellowship, based in Cambridge, MA. About Alnylam Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a
-
Affairs fellowship, based in Cambridge, MA. About Alnylam Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with
-
Global Medical Affairs TTR fellowship, based in Cambridge, MA. About Alnylam Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative
-
Affairs fellowship, based in Cambridge, MA. About Alnylam Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with
-
a two-year Global Medical Affairs Early Assets fellowship, based in Cambridge, MA. About Alnylam Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole
-
positions within in the AMBER co-fund project please visit https://www.euraxess.se/jobs/392999 . The interviews will start in April/May 2026. For more information about AMBER, application and evaluation